Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-02
2007-01-02
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S490000
Reexamination Certificate
active
10451159
ABSTRACT:
The present invention relates to a compound represented by the following formula (I):(wherein, W represents WA-A1-WB- (in which, WAis substituted or unsubstituted aryl, etc., A1is —NR1—, single bond, —C(O)—, etc., and WBis substituted or unsubstituted arylene, etc.), R is single bond, —NH—, —OCH2—, alkenylene, etc., X is —C(O)—, —CH2—, etc., and M is, for example, the following formula:(in which, R11, R12and R13each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14is hydrogen or lower alkyl, Y represents —CH2—O—, etc., Z is substituted or unsubstituted arylene, etc., A2is single bond, etc, and R10is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same.This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VLA-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.
REFERENCES:
patent: 4184658 (1980-01-01), Barahia
patent: 4221815 (1980-09-01), Weyer et al.
patent: 6117901 (2000-09-01), Wu et al.
patent: 6495525 (2002-12-01), Lee et al.
patent: 6756378 (2004-06-01), Baldwin et al.
patent: 2500157 (1976-07-01), None
patent: 23569 (1981-02-01), None
patent: 585155 (1994-03-01), None
patent: 0 842 945 (1998-05-01), None
patent: 60-181081 (1985-09-01), None
patent: 4-112868 (1992-04-01), None
patent: 5-43574 (1993-02-01), None
patent: 2000-344666 (2000-12-01), None
patent: 95/30673 (1995-11-01), None
patent: 96/04267 (1996-02-01), None
patent: WO 96/22966 (1996-08-01), None
patent: 97/02024 (1997-01-01), None
patent: WO 97/03094 (1997-01-01), None
patent: 97/22619 (1997-06-01), None
patent: WO 98/04247 (1998-02-01), None
patent: WO 98/04913 (1998-02-01), None
patent: 98/08818 (1998-03-01), None
patent: 98/22430 (1998-05-01), None
patent: WO 99/33789 (1999-07-01), None
patent: 99/43672 (1999-09-01), None
patent: 99/64392 (1999-12-01), None
patent: WO 99/61421 (1999-12-01), None
patent: WO 00/00477 (2000-01-01), None
patent: 00/05223 (2000-02-01), None
patent: WO 00/05224 (2000-02-01), None
patent: WO 00/15612 (2000-03-01), None
patent: 00/18770 (2000-04-01), None
patent: 00/40088 (2000-07-01), None
patent: WO 00/49005 (2000-08-01), None
patent: WO 00/61580 (2000-10-01), None
patent: 00/66119 (2000-11-01), None
patent: WO 00/68195 (2000-11-01), None
patent: WO 00/68213 (2000-11-01), None
patent: WO 00/68223 (2000-11-01), None
patent: WO 01/00206 (2001-01-01), None
patent: WO 01/12186 (2001-02-01), None
patent: 01/34567 (2001-05-01), None
patent: 01/51487 (2001-07-01), None
patent: WO 01/53295 (2001-07-01), None
patent: WO 01/58871 (2001-08-01), None
patent: WO 01/64640 (2001-09-01), None
patent: WO 01/64659 (2001-09-01), None
patent: 02/04425 (2002-01-01), None
patent: 02/06222 (2002-01-01), None
patent: WO 03/004460 (2003-01-01), None
Craig Zimmerman; “Peptide and peptidomimetic inhibitors of VLA-4,” Exp. Opin. Ther. Patents (1999) 9(2); 129-133, especially p. 130.
Duplantier et al., “Isooxazolyl, oxazolyl, and thiazdylpropionic acid derivatives as potent α4β1 Integrin Antagonists,” Bioorganic & Med. Chem. Lett. 11 (2001) 2593-2596, especially p. 2593.
Yang et al., “VLA-4 Antagonists: Potent Inhibitors of Lymphocyte Migration,” Med. Res. Reviews, vol. 23, No. 3, 369-392 (2003), especially p. 370.
Jefferson W. Tilley, et al., “VLA-4 antagonists”, Drugs of the Future, vol. 26, No. 10, 2001, pp. 985-998.
Ginger X. Yang, et al., “VLA-4 Antagonists: Potent Inhibitors of Lymphocyte Migration”, Medicinal Research Reviews, vol. 23, No. 3, 2003, pp. 369-392.
Craig N. Zimmerman, “Peptide and peptidomimetic inhibitors of VLA-4”, Exp. Opin. Ther. Patents, vol. 9, No. 2 1999, pp. 129-133.
Allen J. Duplantier, et al., “Isoxazolyl, Oxazolyl, and Thiazolylpropionic Acid Derivatives as Potent α4β1Integrin Antagonists”, Bioorganic and Medicinal Chemistry Letters, vol. 11, 2001, pp. 2593-2595.
E. Kudlacz, et al., “Pulmonary Eosinophilia in a Murine Model of Allergic Inflammation is Attenuated by Small Molecule—α4β1 Antagonists”, The Journal of Pharmacology and Experimental Therapeutics, vol. 301, No. 2, May 2002, pp. 747-752.
Daniel M. Scott, et al., “High-Affinity Antagonists of the A4B1 Integrin”, 220thACS National Meeting (Washington, DC)/MEDI, 178, 1 page, 2002.
J. Med. Chem., vol. 43, No. 3, pp. 392-400 2000.
Chiba Jun
Iimura Shin
Machinaga Nobuo
Nakayama Atsushi
Sugimoto Yuichi
Chung Susannah L.
Daiichi Pharmaceutical Co. Ltd.
McKane Joseph K.
LandOfFree
Vla-4 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vla-4 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vla-4 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3757823